Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993358 | 0.86 | CNR1 (0.43) | CNR1HIF1AALDH1A1XDHTSHR | |
| SCHEMBL4099269 | 0.83 | CNR1 (0.48) | CNR1HIF1AALDH1A1XDHCYP17A1 | |
| SCHEMBL4512837 | 0.83 | CNR1 (0.46) | CNR1HIF1AALDH1A1XDHTSHR | |
| SCHEMBL4524872 | 0.82 | CNR1 (0.45) | CNR1HIF1AALDH1A1XDHTSHR | |
| SCHEMBL4522018 | 0.82 | CNR1 (0.46) | CNR1HIF1AALDH1A1TSHRNPC1 | |
| SCHEMBL4531198 | 0.81 | CNR1 (0.43) | CNR1HIF1AALDH1A1TSHRNPC1 | |
| SCHEMBL4514911 | 0.81 | CNR1 (0.46) | CNR1HIF1AALDH1A1TSHRGAA | |
| SCHEMBL4519841 | 0.80 | CNR1 (0.43) | CNR1HIF1AALDH1A1TSHRNPC1 | |
| SCHEMBL2233449 | 0.79 | MAT2A (0.42) | ALDH1A1TSHRNPC1GAAPKM | |
| SCHEMBL1997653 | 0.77 | CDK1 (0.41) | XDHNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | TRPV1, TRPV2, TRPV3 | CNR1 30/4885HIF1A 644/4885ALDH1A1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.